Answers are grounded in this paper and cite their sources.
To the Editor—Despite considerable advances in the diagnosis and treatment of tuberculosis, central nervous system tuberculosis is still a devastating and often life-threatening disease. Despite tuberculostatic and anti-inflammatory co-medication, irreversible neurological damage may ensue from many causes. These include cerebritis, cranial nerve inflammation, aqueduct stenosis and hydrocephalus, vasculitis and stroke, and brain edema that may result in transtentorial or transfalcine herniation. Indeed, currently half of the patients with drug-susceptible tuberculous meningitis die or are left with severe neurological damage [1]. The outcome of multidrug-resistant (MDR) tuberculous meningitis is even more daunting, with a near 100% mortality [2–4]. Conceivably, drug exposure at the site of infection should be optimized to curb the poor prognosis for these patients. Due to a disrupted blood–cerebrospinal fluid (CSF) barrier, the concentrations of antituberculosis drugs in serum and CSF in patients with tuberculous meningitis may be correlated in the early stage of disease. However, during treatment the concentration of antituberculosis drugs in CSF may be reduced when the inflammatory response subsides, resulting in restoration of the blood–CSF barrier [5]. Some second-line antituberculosis drugs have been shown to penetrate well into the CSF (eg, moxifloxacin [6], protionamide, and cycloserine), whereas others do not [1]. In December 2013, bedaquiline (BDQ; Sirturo), a selective inhibitor of the mycobacterial ATP synthase complex [7], became available in Europe for the treatment of MDR tuberculosis. It is not part of standard regimens for MDR tuberculosis according to World Health Organization guidelines. However, one phase 2b study with BDQ added to a background regimen showed significantly faster time to culture conversion compared with the background regimen only [8]. In our tuberculosis center (Beatrixoord, University Medical Center Groningen, the Netherlands), we routinely perform therapeutic drug monitoring for all patients with MDR tuberculosis, with excellent outcomes [9]. We report on a 36-year-old man from Somalia who was treated in our center for MDR tuberculosis of the central nervous system, including meningitis. BDQ was part of his treatment regimen due to resistance and intolerance against several second-line antituberculosis drugs. BDQ was dosed according to the proposed schedule by the manufacturer for pulmonary MDR tuberculosis. To evaluate penetration in CSF, both serum and CSF samples were collected for therapeutic drug monitoring at several time points during 24 hours, with consent of the patient, approximately 6 weeks after starting on BDQ and 11 weeks after start of antituberculosis treatment. CSF samples were obtained through an external lumbar drainage system at L4–L5. Using a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method as described earlier [10], therapeutic levels of BDQ were measured in serum, but not in CSF. In CSF, the BDQ concentrations were undetectably low at all time points (Figure 1). These results show the need for further exploration of BDQ concentration in CSF in an earlier stage of disease, as well as in larger groups. The role of BDQ for treatment of MDR tuberculous meningitis remains unclear; we hypothesize that BDQ may be among second-line antituberculosis drugs with poor penetration in CSF. Bedaquiline concentration over time in serum (solid circles) and cerebrospinal fluid (open circles) after administration of 200 mg bedaquiline 3 times a week (second phase of treatment). Potential conflicts of interest. T. S. W., J.-W. A., and O. W. A. have received support from Janssen-Cilag.
No takes yet. Share an insight, caveat, or question.
Akkerman et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: